AAT Augmentation denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for aat augmentation are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Quantity Limits to AAT Augmentation

Blue Cross Blue Shield plans impose quantity limits on AAT augmentation therapy to control utilization and cost. These limits typically reflect a maximum approved dose or frequency per coverage period, based on the plan's clinical policy. A quantity-limit denial occurs when the amount prescribed or dispensed exceeds the plan's authorized quantity — even if the treating physician has determined that the prescribed amount is clinically appropriate for the patient's weight or disease severity.

Quantity-limit denials on a weight-based therapy like AAT augmentation are particularly common because patients at the higher end of the weight range require correspondingly higher doses to achieve therapeutic levels, and plan quantity limits may not automatically account for individual body weight.

## Why This Is Appealable

ACA §2719 and ERISA §503 entitle you to challenge any adverse benefit determination, including quantity-limit denials. The appeal should establish that the prescribed quantity is consistent with the FDA-approved prescribing label for a patient of the stated weight — without requiring you to publish specific numbers in the appeal itself. Refer the reviewer to the label's dosing section and the patient's documented weight, and let the arithmetic speak for itself. External review is available after exhausting internal appeals, within a four-month window.

## Documentation to Gather

• FDA prescribing label: The dosing section of the current prescribing information establishes the approved dosing basis (typically weight-based). Attach this as an exhibit.
• Patient weight documentation: Current body weight from the clinical record, sufficient for the reviewer (or an external reviewer's pharmacist) to verify that the prescribed quantity matches the label.
• Prescriber justification letter: A letter from the treating physician explaining that the prescribed quantity is clinically necessary and consistent with the approved label for this patient's individual characteristics.
• Infusion records (if applicable): Records of prior infusion amounts actually administered, to establish that the quantity requested is consistent with prior practice.

## Criteria-Mapping Structure

Obtain BCBS's published quantity-limit policy for this specific drug (from the clinical policy bulletin or the formulary document). List the limit and its basis in a left column. In the right column, show — using the FDA label's dosing methodology and the patient's documented weight — why the prescribed quantity is medically necessary and within label. Where BCBS's limit and the label calculation diverge, state the discrepancy clearly and ask the reviewer to apply the clinically appropriate standard.

## Timeline

1. File internal appeal within 180 days of denial. 2. Expedited review (72 hours) is available if the therapy is urgently needed. 3. Standard internal appeal: 30-day decision for pre-service requests. 4. After final internal denial: request external review within 4 months.